Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902219-25-000263
Filing Date
2025-08-05
Accepted
2025-08-05 13:44:38
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10752
2 JOINT FILING AGREEMENT Rule13D_JointFilingAgreement.htm EX-99 4391
  Complete submission text file 0000902219-25-000263.txt   17321
Mailing Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210
Business Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 6179515000
WELLINGTON MANAGEMENT GROUP LLP (Filed by) CIK: 0000902219 (see all company filings)

EIN.: 042683227 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 90 PARK DRIVE MILTON PARK, ABINGDON OXFORDSHIRE X0 OX14 4RY
Business Address 90 PARK DRIVE MILTON PARK, ABINGDON OXFORDSHIRE X0 OX14 4RY 01235 5430281
Immunocore Holdings plc (Subject) CIK: 0001671927 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92246 | Film No.: 251184132
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)